• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Galapagos NV ADR (NQ: GLPG )

    26.93 -0.53 (-1.91%)
    Streaming Delayed Price Updated: 2:06 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Galapagos NV ADR

    < Previous 1 2 3 4 Next >
    Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
    Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T... 
    Via Benzinga
    Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
    The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
    Via Investor's Business Daily
    Exposures Product Safety
    Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    8 Analysts Have This to Say About Galapagos
    Via Benzinga
    Where Galapagos Stands With Analysts
    Via Benzinga
    JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
    Via Benzinga
    Earnings Outlook For Galapagos
    Via Benzinga
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
    FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,... 
    Via Benzinga
    Exposures Product Safety
    GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
    GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
    GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
    BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
    Via Benzinga
    Earnings Preview For Galapagos
    Via Benzinga
    Where Galapagos Stands With Analysts
    Galapagos (NASDAQ:GLPG) has observed the following analyst ratings within the last quarter: 
    Via Benzinga
    Where Galapagos Stands With Analysts
    Analysts have provided the following ratings for Galapagos (NASDAQ:GLPG) within the last quarter: 
    Via Benzinga
    European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
    On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG). 
    Via Benzinga
    GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
    GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
    Via Benzinga
    BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
    Via Benzinga
    Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
    Via Benzinga
    Why Galapagos Stock Is Falling Today
    Galapagos NV (NASDAQ: GLPG) announced the topline results from the DIVERSITY Phase 3 trial of filgotinib during induction and maintenance treatment of biologic-naïve and biologic-experienced patients... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
    Via Benzinga
    Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
    Benzinga 
    Via Benzinga
    On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
    Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
    Upgrades 
    Via Benzinga
    After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
    Via Benzinga
    Expert Ratings for Galapagos
    Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    3 Biotech Stocks to Sell in October
    These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
    Upgrades 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.